AELIX Therapeutics is a clinical stage biotechnology company based in Barcelona, Spain, focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in the field of AIDS. The HIVACAT programme, which aims to develop strategies to prevent and cure HIV and AIDS, is led by IrsiCaixa Aids Research Institute and the Infectious Diseases and AIDS Unit of the Hospital Clínic of Barcelona. The HIVACAT consortium licensed the HTI technology to AELIX Therapeutics for its global development and commercialization. The company was incorporated in November 2015 and completed a €11.5M ($12.5M) Series A funding shortly thereafter through funds managed by Ysios Capital, a Spanish investment firm, Johnson & Johnson – JJDC, Inc., and Caixa Capital Risc, the venture capital division of Spain’s leading group, “la Caixa”.
Meet the team

Jeanne Bolger, MB BCh BAO
Johnson & Johnson Innovation, JJDC, Inc., Board Member
Christian Brander, PhD
Co-Founder, Chief Scientific Officer
José Luis Cabero, Dr Med Sc
Chief Executive Officer
Pablo Cironi, PhD
Caixa Capital Risc, Board Member
Bonaventura Clotet, MD, PhD
Co-Founder, Observer, SAB Member
Margarida Garcia, MSc
Clinical Study Manager
Thomas Hecht, MD
Chairman of the Board of Directors (Independent)
Anne Leselbaum, MD
Vice President Clinical Development
Silvia López
Director of Finance and Operations
Marc Mansour, PhD, MBA
Business Development Consultant
Yves Mertens, PhD
Chief Financial Officer
Philippe Monteyne, MD, PhD
Independent Director
Jordi Naval
Co-Founder and Executive Director
Vesna Radovanovic
Administration Manager
Karen Wagner, PhD
Ysios Capital, Board Member
Jeanne Bolger, MB BCh BAO
Johnson & Johnson Innovation, JJDC, Inc., Board Member
Pablo Cironi, PhD
Caixa Capital Risc, Board Member
Bonaventura Clotet, MD, PhD
Co-Founder, Observer, SAB Member
Thomas Hecht, MD
Chairman of the Board of Directors (Independent)
Philippe Monteyne, MD, PhD
Independent Director
Jordi Naval
Co-Founder and Executive Director
Karen Wagner, PhD
Ysios Capital, Board Member
Christian Brander, PhD
Co-Founder, Chief Scientific Officer
José Luis Cabero, Dr Med Sc
Chief Executive Officer
Anne Leselbaum, MD
Vice President Clinical Development
Marc Mansour, PhD, MBA
Business Development Consultant
Yves Mertens, PhD
Chief Financial Officer